🔴 Adaptive Biotechnologies is trading 4.3% down with no clear company-specific catalyst identified

Adaptive Biotechnologies is trading 4.3% lower at $27.66 on October 1; no clear company-specific catalyst has been identified.

• The sharp intraday decline follows a prior-session close of $28.90.
• Recent coverage includes Goldman Sachs’ September 29 Buy initiation and $35 target; an earlier NCCN guideline update was cited alongside a prior run-up. Neither directly explains the current drop.
• Surging Treasury yields may be adding pressure, but provided index figures show no broad decline exceeding 0.5%.